All > Hnscc > Hepatocellular Carcinoma

Discontinue PD-1/PD-L1-1 inhibitor for Melanoma

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Melanoma+12 MoreDiscontinue PD-1/PD-L1-1 inhibitor - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study whether it is better to stop treatment with PD-1/PD-L1 therapy after one year or continue until disease progression.

Eligible Conditions
  • Bladder Cancer
  • Cervical Cancer
  • Advanced Solid Tumors
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Bile Duct Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Colorectal Cancer
  • Liver Cancer
  • Kidney Cancer
  • Anal Cancer
  • Stomach Cancer
  • Cutaneous Neuroendocrine Carcinoma

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Pembrolizumab
1
Echopulse
1
XmAb®23104

Study Objectives

4 Primary · 3 Secondary · Reporting Duration: Between 4 months and 7.9 months

Month 9
Progression-free Survival (PFS) (at between 2-3.9 months)
Month 9
Progression-free Survival (PFS) (at between 4-7.9 months)
Up to 36 months
Best Objective Response (BOR)
Incidence of irAEs (Immune-Related Adverse Events)
Overall Survival (OS)
Progression-free Survival (PFS)
Time to next treatment

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Pembrolizumab
1
Echopulse
1
XmAb®23104

Trial Design

2 Treatment Groups

Continue Treatment with PD-1/PD-L1 inhibitor
1 of 2
Discontinue Treatment with PD-1/PD-L1-1 inhibitor
1 of 2

Active Control

Experimental Treatment

578 Total Participants · 2 Treatment Groups

Primary Treatment: Discontinue PD-1/PD-L1-1 inhibitor · No Placebo Group · Phase 3

Discontinue Treatment with PD-1/PD-L1-1 inhibitor
Other
Experimental Group · 1 Intervention: Discontinue PD-1/PD-L1-1 inhibitor · Intervention Types: Other
Continue Treatment with PD-1/PD-L1 inhibitor
Drug
ActiveComparator Group · 1 Intervention: Continue PD-1/PD-L1 Inhibitors treatment · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: between 4 months and 7.9 months

Who is running the clinical trial?

Antoinette J WozniakLead Sponsor
Antoinette J Wozniak, MDLead Sponsor
Antoinette J Wozniak, MD, FACP2.33 ReviewsPrincipal Investigator - UPMC Hillman Cancer Center
University of Pittsburgh
1Patient Review
The neglectful care I received resulted in death.

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
All patients must have an advanced, malignant solid tumor (such as NSCLC, bladder, HNSCC, renal, melanoma, cervical Merkel cell and MMR/MSI cancers including colon, rectal cholangio esophageal ovarian uterine anal gastric GE junction hepatocellular and triple negative breast cancer) that is being treated with a PD-1/PD-L1 inhibitor (including pembrolizumab nivolumab atezolizumab durvalumab or avelumab) in accordance to standard care.
Qualified participants have already initiated a course of treatment with chemotherapy, ipilimumab or another PD-1/PD-L1 inhibitor.
Patients must have a sustained degree of wellness as demonstrated by imaging tests taken within 6 weeks of beginning the study.
You have given permission to be randomized into either a group that ceases immunotherapy treatment within one year plus or minus six weeks, or a group that continues the same therapy beyond this timeline.
Patients must have either measurable or non-quantifiable disease according to iRECIST standards.
Participation in a clinical trial is not allowed.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top